Poyurovsky 2002.

Study characteristics
Methods	Randomisation: randomised, no other details Blinding: double‐blind, no other details Duration: 8 weeks Country: Israel
Participants	Diagnosis: DSM‐IV schizophrenia N = 30 Age: 25.5 years Sex: male and female Setting: inpatients History: < 4 weeks of antipsychotics exposure Excluded: unco‐operative, aggressive, and suicidal patients and patients with medical illnesses that could affect body weight
Interventions	Fluoxetine (20 mg/d) in combination with olanzapine (10 mg/d); N = 15 Placebo in combination with olanzapine (10 mg/d); N = 15
Outcomes	Able to use Primary outcomes Weight measures Mean body weight (completers data only) Average change in body weight (ITT analysis of data from all participants randomised) BMI Secondary outcomes Mental state SAPS SANS SAPS/SANS Dimensions (positive, negative, disorganised) HAM‐D
Notes	Performed ITT analysis including dropouts. 74.2% study completers
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Information is unavailable
Allocation concealment (selection bias)	Unclear risk	Information is unavailable
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information is unavailable
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information is unavailable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Quote: "Six subjects withdrew from the study within the first 4 weeks because of lack of response (2 patients receiving fluoxetine) and psychotic exacerbation (2 fluoxetine and 2 placebo patients)." Pg 1058 Comment: only 80% of the study population completed the study, which may effect results due to the small sample size (N = 31), however, ITT analyses reported by the study authors provides similar results as study completers.
Selective reporting (reporting bias)	Unclear risk	Study protocol is unavailable
Other bias	Low risk	No obvious bias